Karyopharm Q2 total rev $37.6M; net loss $32.6M; cuts workforce 20%, guides FY rev $145-160M

Karyopharm Therapeutics Inc.

2023-Q2 EPS reported -$0.59 revenue$76,277,000

Q2 total rev $37.6M (down 5% YoY); net loss $32.6M ($0.29/sh) improved from $49.1M ($0.62/sh).
U.S. XPOVIO net product rev $28.5M (flat YoY); FY 2023 guidance: total rev $145-160M, XPOVIO $110-125M.
Workforce cut ~20%; non-GAAP R&D+SG&A guidance lowered to $240-255M; cash runway extended into late 2025.
Initiated pivotal Phase 3 (XPORT-MF-034) of selinexor+ruxolitinib in JAKi-naïve myelofibrosis; Fast Track from FDA.
Revenue Interest Financing amended: cap raised to 195%, warrants for 250k shares at $2.25, payment date extended to June 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Karyopharm Therapeutics Inc. reported the quarter ended June 30, 2023 results: revenue $37.6 Million. Guidance reaffirmed.

Period: the quarter ended June 30, 2023
Revenue: $37.6 Million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress – Achieved Second Quarter 2023 Total Revenue of $37.6 Million

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-201161

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.